Novo Nordisk filed suit in the U.S. District Court for the District of Delaware on February 9, 2026, alleging that compounded semaglutide injections and pills infringe on its patent covering the active pharmaceutical ingredient semaglutide, which is currently available in commercial form as Ozempic®, Wegovy®, and Rybelsus®. According to the complaint, all compounded versions of drugs containing semaglutide unlawfully incorporate the patented ingredient and circumvent the Food and Drug Administration’s (“FDA”) new drug approval process. Novo Nordisk is seeking a permanent injunction and damages, among other forms of relief.
The Blank Rome regulatory, intellectual property, and litigation teams are closely monitoring these developments. Recent regulatory actions and this newly filed litigation reflect increased federal attention to compounded GLP‑1 drugs, and the legal and enforcement landscape remains dynamic.
[View source.]
